From a conference in May 2017, a comprehensive overview of active surveillance by one of the experts in the field. View video.
Video: Active Surveillance: Protecting Patients from Harm – Dr. Laurence Klotz Read More »
Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months. Read the article here.
Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival Read More »
Immunotherapy is an exciting new field of study that is designed to boost the body’s immune system to fight cancer. It uses materials either made by the body or in a lab to improve, target or restore immune function. There are different types of immunotherapy including vaccines, monoclonal antibodies and non-specific immunotherapies. In prostate cancer, a treatment vaccine helps the body’s immune system fight cancer by training it to recognize and destroy cancer cells. Read the article here.
Single-fraction 19 Gy high dose–rate brachytherapy may be a safe and effective treatment alternative for men with localized prostate cancer, according to study results. Read the article here.
Single-fraction, high-dose brachytherapy may be viable for localized prostate cancer Read More »
Younger age at diagnosis of low-risk prostate cancer was independently associated with decreased risk of disease progression in men managed with active surveillance, researchers reported. Read the article here. Active surveillance is a reasonable option for carefully selected men under 60 with low-risk prostate cancer. However, patients must be surveyed closely and understand the significant risk of ultimately needing treatment. Read the article here.
Active Surveillance in Men under 60 Read More »
The Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer was updated to account for new evidence. Read the article here.
Updated Guideline on Brachytherapy in Prostate Cancer Read More »
According to new data reported at the annual meeting of the European Association of Urology in London, active surveillance of men diagnosed with low-risk prostate cancer was not associated with an elevated risk for metastatic disease at 15 years of follow-up. Read the article here.
15-year metastasis-free survival in men on active surveillance in The Netherlands Read More »
With the goals of working together more collaboratively and to provide higher quality information for patients at the time of decision-making, a prostate cancer community partnership consensus (PCPC) panel was formed among six partnering centers in the Greater Toronto Area. Read the article here.
March 2017 Awareness Night The Prostate Gland and Testosterone: relationship, importance to overall health, and the impact of prostate cancer and treatment on one’s health Dr. Joseph R. LaBossiere, BMSc, MD, MSc, FRCSC Reconstructive Urology Fellow, Sunnybrook Health Sciences Centre CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 58:43 minutes
A new study offers important information to men who are facing difficult decisions about how to treat prostate cancer in its early stages, or whether to treat it at all. Researchers followed patients for 10 years and found no difference in death rates between men who were picked at random to have surgery or radiation, or to rely on “active monitoring” of the cancer, with treatment only if it progressed. Read the article here.
Prostate Cancer Study Details Value of Treatments Read More »